Relatively high DFS in BCL-2-positive TN tumours obtained by us could also confirm results of earlier reports, showing that a subset of TN breast cancer patients responded to standard chemotherapy and had survival rate similar to women with other breast cancer immunophenotypes (Liedtke et al. 2008). This evidence concerns the gene BCL2 and breast carcinoma.